These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33385522)

  • 1. Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis.
    Kittipibul V; Blumer V; Angsubhakorn N; Hernandez GA; Chaparro S; Tedford RJ; Agarwal R
    J Card Fail; 2021 Apr; 27(4):477-485. PubMed ID: 33385522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.
    Gulati G; Grandin EW; Kennedy K; Cabezas F; DeNofrio DD; Kociol R; Rame JE; Pagani FD; Kirklin JK; Kormos RL; Teuteberg J; Kiernan M
    Circ Heart Fail; 2019 Jun; 12(6):e005537. PubMed ID: 31181953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase-5 inhibitors for left ventricular assist device implantation complicated by right ventricular failure.
    Papathanasiou M; Jakstaite AM; Mincu R; Wernhart S; Ruhparwar A; Rassaf T; Luedike P
    ESC Heart Fail; 2023 Aug; 10(4):2728-2733. PubMed ID: 37056058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation.
    Jakstaite AM; Luedike P; Schmack B; Pizanis N; Riebisch M; Weymann A; Kamler M; Ruhparwar A; Rassaf T; Papathanasiou M
    ESC Heart Fail; 2021 Aug; 8(4):2419-2427. PubMed ID: 33821578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
    Hwang IC; Kim YJ; Park JB; Yoon YE; Lee SP; Kim HK; Cho GY; Sohn DW
    BMC Cardiovasc Disord; 2017 Jun; 17(1):150. PubMed ID: 28606099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.
    De Vecchis R; Cesaro A; Ariano C
    Minerva Cardioangiol; 2018 Oct; 66(5):659-670. PubMed ID: 28398017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis.
    Grandin EW; Gulati G; Nunez JI; Kennedy K; Rame JE; Atluri P; Pagani FD; Kirklin JK; Kormos RL; Teuteberg J; Kiernan MS
    Circ Heart Fail; 2022 Apr; 15(4):e008613. PubMed ID: 35332780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.
    Xanthopoulos A; Tryposkiadis K; Triposkiadis F; Fukamachi K; Soltesz EG; Young JB; Wolski K; Blackstone EH; Starling RC
    J Am Heart Assoc; 2020 Jul; 9(14):e015897. PubMed ID: 32648508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-operative atrial fibrillation and early right ventricular failure after left ventricular assist device implantation: a systematic review and meta-analysis.
    Kittipibul V; Blumer V; Hernandez GA; Fudim M; Flowers R; Chaparro S; Agarwal R
    Am Heart J; 2021 Sep; 239():120-128. PubMed ID: 34038705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex disparities in left ventricular assist device implantation outcomes: A systematic review and meta-analysis of over 50 000 patients.
    Arjomandi Rad A; Kapadia S; Zubarevich A; Nanchahal S; Van den Eynde J; Vardanyan R; Bareka M; Krasopoulos G; Quarto C; Ruhparwar A; Athanasiou T; Weymann A
    Artif Organs; 2023 Feb; 47(2):273-289. PubMed ID: 36461903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation.
    Baker WL; Radojevic J; Gluck JA
    Artif Organs; 2016 Feb; 40(2):123-8. PubMed ID: 26043796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil in Left Ventricular Assist Device Is Safe and Well-Tolerated.
    Ravichandran AK; LaRue SJ; Novak E; Joseph SA; Schilling JD
    ASAIO J; 2018; 64(2):280-281. PubMed ID: 28692527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies.
    Bellavia D; Iacovoni A; Scardulla C; Moja L; Pilato M; Kushwaha SS; Senni M; Clemenza F; Agnese V; Falletta C; Romano G; Maalouf J; Dandel M
    Eur J Heart Fail; 2017 Jul; 19(7):926-946. PubMed ID: 28371221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices.
    Xanthopoulos A; Wolski K; Wang Q; Blackstone EH; Randhawa VK; Soltesz EG; Young JB; Nissen SE; Estep JD; Triposkiadis F; Starling RC
    JACC Heart Fail; 2022 Feb; 10(2):89-100. PubMed ID: 35115092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
    Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
    Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Adverse Events With Phosphodiesterase 5 Inhibitors Post LVAD Implantation: Is It Time for a Randomized Trial?
    Starling RC; Xanthopoulos A; Nissen SE; Triposkiadis F
    J Card Fail; 2022 Dec; 28(12):1733-1737. PubMed ID: 35690316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Implant Phosphodiesterase-5 Inhibitors in Patients with Left Ventricular Assist Device: A Systematic Review and Meta-Analysis.
    Xanthopoulos A; Magouliotis DE; Tryposkiadis K; Zotos PA; Spiliopoulos K; Athanasiou T; Giamouzis G; Skoularigis J; Starling RC; Triposkiadis F
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure.
    Cavarretta E; Marullo AGM; Sciarretta S; Benedetto U; Greco E; Roever L; Tonelli E; Peruzzi M; Iaccarino A; Biondi-Zoccai G; Frati G
    Eur J Cardiothorac Surg; 2019 Mar; 55(3):461-467. PubMed ID: 30137270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.
    Giannetta E; Feola T; Gianfrilli D; Pofi R; Dall'Armi V; Badagliacca R; Barbagallo F; Lenzi A; Isidori AM
    BMC Med; 2014 Oct; 12():185. PubMed ID: 25330139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor.
    Hamdan R; Mansour H; Nassar P; Saab M
    Artif Organs; 2014 Nov; 38(11):963-7. PubMed ID: 24689700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.